Swiss Parliament’s Vote For Medtech Innovation Succeeds
Lower house follows example of upper house in granting mandate for medtech change
Another key stage has been reached in Switzerland’s bid to enable US FDA-approved medtech to be used in the local population.
You may also be interested in...
Many well respected medtech experts have taken to LinkedIn to voice their opinions on the European Commission’s proposals to address the growing challenges with the implementation of the MDR. A glance at their views shows just how split opinions are.
The Swiss medtech market is now served by 1,200 companies fewer than when its MRA with the EU was still in force. A renewal of the agreement is not a lost hope for the local industry, but at present it is a distant prospect.
Architects of the major reform of secondary care reimbursement have asked for the input of hospitals just once, the DKG hospital federation complains. Meanwhile, many clinics are reportedly facing insolvency later this year.